Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force
Year: 2010
Type: article
Abstract: The following were searched systematically for publications in English, until June, 2009: PubMed – from 1950 Medline – from 1950 EMBASE – from 1980 CINAHL (Cumulative Index to Nursing and Allied Health Literature) – from 1982 The Cochrane Library 2008, Issue 3 DARE CRD Website (Centre for Reviews and Dissemination) SRI (Systematic Review Initiative) Handsearch Databases Search terms included: Transfusion-associated graft-versus-host disease, Transfusion-associated graft-versus-host, TA-GvHD. The last guideline covering this topic was published in 1996 (British Committee for Standards in Haematology (BCSH) Blood Transfusion Task Force, 1996. The writing group produced the new draft guideline, which was subsequently revised by consensus by members of the Haemato-oncology and Blood Transfusion Task Forces of the BCSH. The guideline was then reviewed by a sounding board of approximately 100 UK haematologists, the BCSH and the committee of the British Society for Haematology and amended, again by consensus. Criteria used to quote levels and grades of evidence are according to the GRADE system (Guyatt et al, 2006). Strong recommendations (grade 1, 'recommended') are made when there is confidence that the benefits either do or do not outweigh the harm and burden and costs of treatment. Where the magnitude of benefit or not is less certain a weaker grade 2 recommendation ('suggested') is made. Grade 1 recommendations can be applied uniformly to most patients whereas grade 2 recommendations require judicious application. The quality of evidence is graded as A (high quality randomized clinical trials), moderate (B) or low (C). This publication reports the key recommendations of the Writing Group. It is also accessible at http://www.bcshguidelines.com. To provide healthcare professionals with clear guidance on situations when the use of irradiated blood components is appropriate, and to document any recognized advantages and disadvantages of their use. The guidance may not be appropriate in all patient situations, and individual circumstances may dictate an alternative approach. Studies of patients in all age groups have been considered. • Use of X-irradiation as an alternative to gamma irradiation. • All cases of transfusion-associated graft-versus host disease and all episodes where non-irradiated components are transfused to high risk patients should be reported to national haemovigilance systems [in the UK, the Serious Hazards of Transfusion (SHOT) initiative]. • Irradiated components are recommended for aplastic anaemia patients receiving immunosuppressive therapy with anti-thymocyte globulin (ATG). • Indication for irradiated components extended to newer purine analogues and related drugs until evidence of their safety is forthcoming (e.g. bendamustine and clofarabine). • Irradiated components indicated for patients receiving the biological immunosuppressive agent alemtuzumab (anti-CD52), but not rituximab (anti-CD20) – regular review will be needed as new biological agents enter clinical practice. • All cases of transfusion-associated graft-versus-host disease (TA-GvHD) should be reported to the national haemovigilance system, as should all 'near misses' where non-irradiated components are transfused to high-risk patients without incident (1B). • Gamma or X-irradiation of blood components, by validated systems, is the recommended procedure to prevent TA-GvHD (1B). • The minimum dose achieved in the irradiated volume should be 25 Gy, with no part receiving more than 50 Gy (1B). • For at-risk patients, all red cell, platelet and granulocyte concentrates should be irradiated except cryopreserved red cells after deglycerolization. It is not necessary to irradiate fresh frozen plasma, cryoprecipitate or fractionated plasma products (1B). • All donations from first- or second-degree relatives should be irradiated, even if the patient is immunocompetent (1B). • All human leucocyte antigen (HLA)-selected components should be irradiated, even if the patient is immunocompetent (2C). • Red cells may be irradiated at any time up to 14 d after collection, and thereafter may be stored for a further 14 d. Where the patient is at particular risk from hyperkalaemia, e.g. intrauterine or neonatal exchange transfusion, it is recommended that red cells be transfused within 24 h of irradiation or that the cells are washed (1A). • Platelets can be irradiated at any stage during storage and can thereafter be stored up to their normal shelf life after collection (1A). • All granulocyte components should be irradiated before issue and transfused with minimum delay (1C). • Irradiated components not used for the intended recipient can safely be returned to stock to be used for recipients who do not require irradiated components. The reduction in shelf life must be observed (1B). • All irradiated components should be labelled as such, using an approved bar code label. Each unit should be monitored using a radiation-sensitive device, and the result permanently recorded, manually or by computer (1C). • All blood for intrauterine transfusion (IUT) should be irradiated (1B). It is essential to irradiate blood for neonatal exchange transfusion (ET) if there has been a previous IUT or if the donation comes from a first- or second-degree relative (1B). For other neonatal ET cases, irradiation is recommended provided this does not unduly delay transfusion (1C). For IUT and ET, blood should be transfused within 24 h of irradiation and, in any case, by 5 d or less from collection (1A). • It is not necessary to irradiate red cells for routine 'top-up' transfusions of premature or term infants unless either there has been a previous IUT, in which case irradiated components should be administered until 6 months after the expected delivery date (40 weeks gestation), or the donation has come from a first- or second-degree relative (2C). • Platelets transfused in utero to treat alloimmune thrombocytopenia should be irradiated and any subsequent red cell or platelet transfusions irradiated until 6 months after the expected date of delivery (40 weeks gestation). There is no need to irradiate other platelet transfusions for pre-term or term infants, unless they have been donated by first- or second-degree relatives (1C). • All severe T lymphocyte immunodeficiency syndromes should be considered as indications for irradiation of cellular blood components. Once a diagnosis of immunodeficiency has been suspected, irradiated components should be given while further diagnostic tests are being undertaken. A clinical immunologist should be consulted for advice in cases where there is uncertainty (1A). • There is no indication for routine irradiation of cellular blood components for infants or children who are suffering from a common viral infection, who are human immunodeficiency virus (HIV) antibody positive, or who have acquired immunodeficiency syndrome (AIDS). However, this should be kept under review. There is also no indication for routine irradiation of cellular blood components for adults who are HIV antibody positive or who have AIDS (2B). • There is no need to irradiate red cells or platelets for infants undergoing cardiac surgery unless clinical or laboratory features suggest a coexisting T lymphocyte immunodeficiency syndrome (2B). • It is not necessary to irradiate red cells or platelets for adults or children with acute leukaemia, except for HLA-selected platelets or donations from first- or second-degree relatives (1B). • All recipients of allogeneic haemopoietic stem cell transplantation (SCT) must receive irradiated blood components from the time of initiation of conditioning chemoradiotherapy (1B). This should be continued while the patient continues to receive graft-versus-host disease (GvHD) prophylaxis, i.e. usually for 6 months post-transplant, or until lymphocytes are >1 × 109/l. If chronic GvHD is present or if continued immunosuppressive treatment is required, irradiated blood components should be given indefinitely (2C). Allogeneic blood transfused to bone marrow and peripheral blood stem cell donors 7 d prior to or during the harvest should also be irradiated (2C). • Patients undergoing bone marrow or peripheral blood stem cell 'harvesting' for future autologous re-infusion should receive irradiated cellular blood components during and for 7 d before the bone marrow/stem cell harvest to prevent the collection of viable allogeneic T lymphocytes which can potentially withstand cryopreservation (2C). • All patients undergoing autologous bone marrow transplant or peripheral blood stem cell transplant should receive irradiated cellular blood components from initiation of conditioning chemo/radiotherapy until 3 months post-transplant (6 months if total body irradiation was used in conditioning) (2C). • All adults and children with Hodgkin lymphoma at any stage of the disease should have irradiated red cells and platelets for life (1B). • Patients treated with purine analogue drugs (fludarabine, cladribine and deoxycoformicin) should receive irradiated blood components indefinitely (1B). The situation with other purine antagonists and new and related agents, such as bendamustine and clofarabine, is unclear, but use of irradiated blood components is recommended as these agents have a similar mode of action. Irradiated blood components should be used after alemtuzumab (anti-CD52) therapy. Their use after rituximab (anti-CD20) is not recommended at this time. As new potent immunosupressive drugs and biological agents are introduced into practice there is a need for regular review of these recommendations (2C). • It is not necessary to irradiate blood components for patients undergoing routine surgery, those with solid tumours HIV infection, autoimmune diseases or after solid organ transplantation (unless alemtuzumab (anti-CD52) has been used in the conditioning regimen). The effects of new regimens of chemo- and immunotherapy entering clinical practice must continue to be monitored (2C). • In view of the recent switch from horse anti-thymocyte globulin (ATG) to the more immunosuppressive rabbit ATG, we now recommend use of irradiated blood components for aplastic anaemia patients receiving immunosuppressive therapy with ATG (and/or alemtuzumab) (2C). We cannot make a firm recommendation as to how long irradiated components should continue to be used after ATG administration. • Patients at risk of TA-GvHD should be made aware of their need for irradiated blood components and provided with appropriate written information and an alert-card for clinical staff. We endorse the recommendations from SHOT (http://www.shotuk.org) relating to improved clinical and laboratory awareness, documentation and communication of special requirements for transfusion, including irradiated components. Initiatives to improve laboratory and clinical information management systems (including IT links with Pharmacy and diagnostic services to highlight 'at risk' patients) should be incorporated into local policies and regularly audited. Poor communication between centres involved in 'shared care' of patients is a well-reported hazard and the development of a standardized national system for recording and transferring details of special transfusion requirements is an urgent requirement to improve patient safety. (2C). More detailed recommendations on ensuring special transfusion requirements are met are given in the BCSH Administration of Blood Components Guideline 2009 (http://www.bcshguidelines.com). Information leaflets for patients and healthcare staff are available from the UK Blood Services. Table I depicts a summary of the key recommendations. TA-GvHD is a very rare but usually fatal complication following transfusion of lymphocyte-containing blood components. Although the first reports concerned cases where viable allogeneic lymphocytes had been transfused into immunosuppressed recipients (von Fliedner et al, 1982; Burns et al, 1984; Anderson & Weinstein, 1990), it became apparent that non-immunosuppressed patients could also experience this problem, particularly if the blood components they received came from an HLA haploidentical unrelated donor or family member (Ohto et al, 1992; Aoun et al, 2003; Serefhanoglu et al, 2005; Triulzi et al, 2006; Agbaht et al, 2007). The risk associated with an individual transfusion depends on the number and viability of contaminating lymphocytes, susceptibility of the recipient's immune system to their engraftment and degree of immunological (HLA) disparity between donor and patient. The minimum number of transfused lymphocytes necessary to provoke a GvHD reaction is unknown and may vary by clinical settings. Until recently, gamma irradiation of cellular blood components has been the mainstay of TA-GvHD prevention and practice was standardized in the UK following publication of the 1996 version of this BCSH Guideline (BCSH Blood Transfusion Task Force, 1996). TA-GvHD is a potential complication of transfusion of any blood component containing viable T lymphocytes when there is disparity in the histocompatibility antigens between donor and recipient. As well as the classical skin, gut and liver involvement seen in GvHD occurring after allogeneic stem cell transplantation, TA-GvHD is characterized by profound marrow hypoplasia and mortality in excess of 90% (Aoun et al, 2003; Williamson et al, 2007). There is a particular risk of TA-GvHD when the donor and patient share an HLA haplotype, as occurs within families (Petz et al,1993), or in populations with restricted haplotype diversity (Yasuura et al, 2000). In the Japanese population, the incidence of TA-GvHD is 10–20 times higher than in the North American Caucasian population. (Shivdasani et al,1993). The early features are fever, maculopapular skin rash, diarrhoea and hepatitis occurring 1–2 weeks after transfusion. Bone marrow involvement produces severe hypoplasia with profound pancytopenia. Diagnosis is usually made by biopsy of skin, gut or liver supported by evidence of persistence of donor lymphocytes. The presence of cells of donor origin may be demonstrated by polymerase chain reaction in peripheral blood (Utter et al, 2007) or short tandem repeat analysis using peripheral blood and skin biopsies from affected and non-affected sites in the patient, and peripheral blood samples from the implicated donors (Sage et al, 2005). Since its inception in 1996, the UK Serious Hazards of Blood Transfusion (SHOT) scheme has recorded 13 fatal cases of TA-GvHD (Stainsby et al, 2006; Taylor et al, 2009). Only two cases have been reported since the introduction of universal prestorage leucodepletion in the UK (Williamson et al, 2007) and no cases have been reported since 2001. Between 1996 and 2008, SHOT received reports of 405 cases where non-irradiated components had been transfused to high-risk recipients, many of whom had received the purine analogue fludarabine, but none developed TA-GvHD. This implies that prestorage leucodepletion has significantly reduced, if not abolished, the risk of TA-GvHD (Williamson et al, 2007). • All cases of transfusion-associated graft-versus-host disease (TA-GvHD) should be reported to the national haemovigilance system, as should all 'near misses' where non-irradiated components are transfused to high-risk patients without incident. (Grade 1 recommendation; level B evidence). The major technology for preventing TA-GvHD is irradiation of blood components to inactivate residual lymphocytes. Gamma rays and X-rays are similar in their ability to inactivate T lymphocytes in blood components at a given absorbed dose. Gamma-irradiators are expensive, and eventual decommissioning and disposal present significant difficulties. These highly radioactive cores may present a security risk in hospital settings. As the source decays, regular recalibration is required and irradiation time progressively increases. Dedicated X-ray blood irradiators are now available, have been widely used in North America for several years and are being introduced by the UK Transfusion Services. X-ray irradiation machines are less expensive and the absence of a radioactive source results in fewer regulatory requirements (Janatpour et al, 2005). Published data indicate that the small differences in red cell permeability found between X- and gamma-irradiated components are not clinically significant (Janatpour et al, 2005). Further work, commissioned by the Joint Professional Advisory Committee of the UK Transfusion Services on blood components irradiated using the Raycell X-irradiator, concluded that gamma and X-irradiation can be regarded as equivalent and both are suitable and safe for clinical use. • Gamma or X-irradiation of blood components, by validated systems, is the recommended procedure to prevent TA-GvHD. (Grade 1 recommendation; level B evidence). Studies using sensitive-limiting dilution assays indicate that a dose of 25 Gy, measured at the mid-plane of a component, completely abolishes mixed lymphocyte response (Pelszynski et al, 1994). The American Association of Blood Banks (AABB) recommends a dose of 25 Gy to the central area of the component with no portion receiving <15 Gy (AABB 2006). The Japanese Society of Blood Transfusion's Guidelines recommend a similar dose (Asai et al, 2000). In the UK, a minimum of 25 Gy is recommended, but with the dose to any bag in the container not exceeding 50 Gy. To ensure this dose distribution is achieved, consultation with supporting physicists is mandatory. (Moroff & Luban, 1997; Moroff et al, 1997). • The minimum dose achieved in the irradiation volume should be 25 Gy, with no part receiving more than 50 Gy. (Grade 1 recommendation; level B evidence). Lymphocyte viability is retained in stored red cells for at least 3 weeks and TA-GvHD has been reported after transfusion of whole blood, red cells, platelets and granulocytes (Weiden et al, 1981). TA-GvHD has not been described following transfusion of frozen deglycerolized red cells, which are thoroughly washed free of leucocytes after thawing. TA-GvHD has not been described following transfusion of cryoprecipitate, fresh frozen plasma or fractionated plasma products, such as clotting factor concentrates, albumin and intravenous immunoglobulin. • For at-risk patients, all red cell, platelet and granulocyte components should be irradiated, except cryopreserved red cells after deglycerolization. It is not necessary to irradiate fresh frozen plasma, cryoprecipitate or fractionated plasma. (Grade 1 recommendation; level B evidence). Because of the sharing of HLA haplotypes, donations from family members pose a particular risk of TA-GvHD. Red cells, granulocytes, platelets and fresh plasma have all been implicated in TA-GvHD after transfusion from family members (Agbaht et al,2007), and there is an increased risk with donations from both first- and second-degree relatives. Several cases of TA-GvHD have been reported from Japan, where limited diversity of HLA haplotypes in the population increases the chance of a transfusion recipient receiving blood from a HLA haploidentical or HLA-identical donor (Ohto & Anderson, 1996). These observations are of relevance for patients receiving HLA-selected platelet concentrates from non-family members because of alloimmune refractoriness to random donor platelets. This would be expected to increase the risk of TA-GvHD, especially if the platelet donor is homozygous for one of the recipient HLA-haplotypes (analogous to donations within families or within racial groups of limited genetic A case of TA-GvHD in an immunocompetent recipient following transfusion of blood components from an unrelated HLA homozygous donor was reported et al, and more cases were reported from in immunocompetent recipients who had received non-irradiated blood from relatives (Agbaht et al, 2007). The risk from HLA-selected platelets where the donor is not homozygous is However, many transfusion centres now of homozygous donors for patients, and in practice it is more to recommend irradiation of all HLA-selected than risk the of • All transfusions from first- or second-degree relatives should be irradiated, even if the patient is immunocompetent (Grade 1 recommendation; level B evidence). • All HLA-selected platelets should be irradiated, even if the patient is (Grade 2 recommendation; level evidence). irradiation of blood components a The is expected to with of the to Red cells can be irradiated up to 14 d after collection and stored for at least a further 14 d without significant of viability & Anderson, Gamma irradiation may result in red cell after more is the minimum et al, gamma and X-irradiation of red cells result in of and an increase in the level of (Moroff et al, et al, 2005; et al, 2005). transfusions given at do not a risk of hyperkalaemia, even when given to premature may be clinically in such as neonatal exchange transfusion or intrauterine transfusion. of plasma and of irradiated red cells is not considered necessary if this procedure is the washed cells should be transfused as as within levels are increased in stored irradiated red cell components et al, but within has no clinically significant on red cell or levels et • Red cells may be irradiated at any time up to 14 d after collection, and thereafter stored for a further 14 d from irradiation. Where the patient is at particular risk from hyperkalaemia, e.g. intrauterine or neonatal exchange transfusion, it is recommended that red cells be transfused within 24 h of irradiation or that the cells are (Grade 1 recommendation; level A evidence). Gamma irradiation 50 Gy has not been to significant clinical in platelet et al, et al, et al, 1994). • Platelets can be irradiated at any stage during storage and can thereafter be stored up to their normal shelf life after (Grade 1 recommendation; level A evidence). The evidence for irradiation to granulocyte is but in any case granulocyte products should be transfused as as after irradiation et al, et al, • All granulocytes should be irradiated before issue and transfused with minimum (Grade 1 recommendation; level evidence). It is that the dose of gamma irradiation to blood components significantly the dose for such cells at high dose in cell than of Gamma irradiation can and could result in of the recipient et al, 2003; et al, 2007). cases have been reported and the significantly those associated with such of of from the transfusion is a risk for recipients of transfusions of irradiated components et al, particularly for The of irradiation on the many new and potentially used in the of blood and • Irradiated components not used for the intended recipient can safely be returned to stock to be used for recipients who do not require irradiated components. The reduction in shelf life must be (Grade 1 recommendation; level B evidence). Irradiated components must be by an approved label. The should be and the date of irradiation and any reduction in shelf bar code should be that components have been irradiated is that are to irradiation and from to are The dose at which the to must be on the label. We recommend using a radiation-sensitive on can also be using The use of radiation-sensitive does not the need for regular and There should be a of all irradiated, including details of irradiation and donation component the of when irradiation was and by • All irradiated should be labelled as such, using an approved bar code label. Each unit should be monitored using a radiation-sensitive device, and the result should be permanently recorded, manually or by (Grade 1 recommendation; level evidence). at risk of TA-GvHD. The especially if may be at particular risk of TA-GvHD because of immune lymphocytes may be found in the neonatal weeks after exchange transfusion (ET) et al, and allogeneic cells have been after intrauterine transfusion (IUT) for disease of the and years after transfusion in cases of TA-GvHD reported in immune infants have in the of IUT by ET et al, or immune IUT the reported cases of TA-GvHD following IUT from unrelated donors et al, it is not to recommend irradiation in the of a transfusion of fresh blood to a very recipient. IUT and subsequent exchange transfusion. Although reports are the published evidence a of irradiation of blood for IUT and any subsequent et al, transfusion cases of TA-GvHD have been reported after ET in pre-term and term infants et al, et the of irradiation of blood for ET in either pre-term or term infants is but not mandatory. The risk of TA-GvHD must be those of any delay in transfusion while irradiation is • All blood for intrauterine transfusion (IUT) should be (Grade 1 recommendation; level B evidence). • Blood for neonatal exchange transfusion (ET) must be irradiated if there has been a previous IUT or if the donation comes from a first- or second-degree (Grade 1 recommendation; level B evidence). • For other neonatal ET cases, irradiation is recommended provided this does not unduly delay transfusion. (Grade 1 recommendation; level evidence). • For IUT and ET, blood should be transfused within 24 h of irradiation and, in any case, by 5 d or less from (Grade 1 recommendation; level A evidence). infants are transfused there are reports of TA-GvHD (Ohto & Anderson, 1996). age the ability of transfusions to and the term or of to transfused in the of transfusions associated with there has been one reported case of TA-GvHD et al, and these infants do not to be at & • It is not necessary to irradiate red cells for routine 'top-up' transfusions of premature or term infants unless either there has been a previous IUT, in which case irradiated components should be administered until 6 months after the expected delivery date (40 weeks gestation), or the donation has come from a first- or second-degree (Grade 2 recommendation; level evidence). There have been no reported cases of TA-GvHD following platelet transfusion but as platelets may small of residual lymphocytes, the recommendations for red cell transfusion should also to platelets. should be on platelets transfused in utero to treat alloimmune thrombocytopenia and on platelet transfusions given after to infants who have received either red cells or platelets in utero for 6 months after the expected delivery • Platelets transfused in utero to treat alloimmune thrombocytopenia should be irradiated and any subsequent red cell or platelet transfusions irradiated until 6 months after the expected date of delivery (40 weeks gestation). There is no need to irradiate other platelet transfusions for pre-term or term infants, unless they have been donated by first- or second-degree relatives. (Grade 1 recommendation; level evidence). There have been no cases of TA-GvHD to However, because these components are with lymphocytes and transfused it is to
Source: British Journal of Haematology
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2058442870
